Skip to main content

Table 1 Relative MCL-1 and BAX mRNA expression levels post-treatment (21 days) with docetaxel (T), carboplatin (C), trastuzumab (H) and/or lapatinib (L) in HER2-positive breast tumours15

From: Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

Pt no. Treatment regimen Fold change in mRNA post-treatment
MCL-1 BAX
TCHL_39 TCH 1.1 0.9
TCHL_45 TCH 1.6 0.7
TCHL_50 TCH 1.0 0.8
TCHL_6 TCH 1.4 1.2
TCHL_29 TCL 1.0 1.2
TCHL_44 TCHL 0.9 1.1
TCHL_54 TCHL 1.6 0.7
TCHL_7 TCHL 1.3 0.8
  1. Tumours with an increase in MCL-1 (≥1.2) and a decrease in BAX (≤0.8) are highlighted in bold